REGN — Regeneron Pharmaceuticals, Inc.
Is REGN overbought or oversold? Here is the current MarketMoodz read.
Regeneron Pharmaceuticals, Inc. (REGN) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $735.20. The rating moved from Oversold to Neutral on October 2, 2026.
- Public ratingNeutral (as of October 3, 2026)
- Last close$735.20
- Last changeMoved from Oversold to Neutral on October 2, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
Regeneron Pharmaceuticals, Inc. (REGN) benefits from leading commercial franchises and a productive biologics R&D engine with strong balance-sheet support for ongoing development and strategic flexibility. The company’s partnership model and in-house technical platforms underpin durable cash generation and pipeline optionality, while late-stage asset investor interest provides potential valuation support. Near-term sentiment may be constrained by macro risk-off conditions and policy-driven pricing pressure, but the combination of earnings resilience and high-quality pipeline catalysts support upside over the next month if clinical and commercial execution remain solid.
Key factors
- Durable commercial franchises with high-margin flagship products (EYLEA, Dupixent partnership) driving steady cash flow and funding R&D
- Deep pipeline and platform capabilities (monoclonal antibody discovery, bispecifics, in‑house manufacturing) supporting mid-to-long-term growth and M&A optionality
- Strong balance sheet and historically healthy free cash flow that support clinical development, potential opportunistic bolt-on acquisitions, and shareholder returns
- Favorable investor appetite for select late-stage biologics and insider/specialist conviction in high-quality biotech assets that can underpin valuation support
- Strategic alliances (notably with Sanofi) that broaden commercial reach and risk-share large indication launches
- Recent broad market risk-off tone and defensive flows could create short-term share volatility but also buying opportunities in a high-quality biopharma name
Risks
- Policy and payer pressure including Medicare drug-price negotiation (IRA) that could compress pricing and access for higher-cost therapies
- Biosimilar competition risk to key biologics over time and pricing pressure from PBMs and payers
- Clinical trial setbacks or regulatory delays for late-stage pipeline assets that would materially affect forward growth expectations
- Concentration risk from dependence on a few high-revenue products; disappointing sales/market share shifts would weigh on financials
- Macro-driven market volatility and episodes of risk-off sentiment that reduce appetite for healthcare cyclicality and delay launches/partnerships
- Manufacturing, supply-chain disruptions or litigation that could impair product availability or increase costs
Latest MarketMoodz coverage
- FDA Selects Firms for PreCheck to Speed New Drug Plants2026-06-29
- Salesforce reportedly to buy Fin for $3.6B to beef up Agentforce AI2026-06-15
- Regeneron Strikes Deal With Trump Admin to Cut Drug Prices2026-04-24
- Regeneron Price Concessions Under Trump Policy; Free Hearing-Loss Therapy2026-04-23
- FDA Expands Dupixent Use as Sanofi Reports Earnings Beat2026-04-23
See today's live rating, score and targets
Members see the live hourly rating for REGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.